Although we acknowledge that subset numbers in this post hoc analysis may be too small to allow definitive conclusions , the data suggest that aprepitant triple therapy provides a benefit over control therapy for the prevention of CINV in patients receiving anthracycline and cyclophosphamide ( AC ) - or non-AC-based moderately emetogenic chemotherapy across age , gender , and region .